About Us

As Chairman of the Irradiation Panel, Samuel serves as the principal leader and official representative of the organization, a role reflected in the Panel’s leadership structure where the Chairman is listed as the primary point of contact. He represents the Panel in interactions with industry stakeholders, regulatory authorities, and partner organizations, ensuring the Panel maintains its reputation as a recognized body of experts in the irradiation processing industry.

He is responsible for defining and communicating the strategic direction of the Panel, including its vision, mission, and future roadmap. His leadership ensures alignment with the Panel’s mission to support industry challenges, contribute to standardization and regulatory discussions, promote emerging technologies, and deliver relevant educational initiatives.

He oversees governance by chairing the Annual General Meeting, facilitating discussions, and coordinating the work of the executive team, which includes the Deputy Chair, Secretary, Treasurer, and working group leads. He also ensures effective coordination among the Irradiation, Microbiology and Education & Training working groups, aligning their activities with the Panel’s strategic objectives and fostering collaboration.

He plays a key role in sustaining engagement across the radiation‑processing industry by encouraging collaboration, supporting member value, and ensuring the Panel remains relevant as technologies evolve—for example with the increasing emphasis on X‑ray irradiation. He also supports the integration of new or returning member organizations and strengthens the Panel’s network.

Samuel is also involved in promoting and facilitating the application of ionizing radiation technologies. He has a strong focus on the radiation application effects on materials used in single use systems for biopharmaceutical processes. He co-chairs and attends X-ray implementation initiatives in industry groups/associations such as the BPSA and the BioPhorum, making also the links with regulatory bodies (FDA/EMA/PMDA/etc.) with BARDA. He is also a company representative (L2) for the Advanced Therapy Medicinal Products (ATMPs) BioPhorum serving as a collaborative platform to advance ATMP development and manufacturing, including cell, gene, and RNA therapies.